Preferred Label : ritonavir;

MeSH definition : An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.;

CISMeF synonym : 538, ABT;

MeSH hyponym : ABT 538; norvir; ABT-538; ABT538;

Wikipedia link : https://en.wikipedia.org/wiki/Ritonavir;

Is substance : O;

UNII : O3J8G9O825;

InChIKey : NCDNCNXCDXHOMX-XGKFQTDJSA-N;

Details


Main resources

You can consult :

An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.

https://www.inesss.qc.ca/covid-19/affections-post-covid-et-nirmatrelvir-/-ritonavir.html
2023
Canada
drug evaluation
disease
ritonavir
affect, nos
affect
nirmatrelvir
nirmatrelvir and ritonavir drug combination
disease, nos

---
https://ansm.sante.fr/actualites/traitements-contre-la-covid-19-la-commission-europeenne-accorde-une-autorisation-de-mise-sur-le-marche-au-paxlovid
2022
false
false
false
France
French
drug approval
europe
drug combinations
drug information
ritonavir
lactams
proline
leucine
nitriles
antiviral agents
COVID-19
adult
pregnancy
Anti-SARS-CoV-2 Polyclonal Antibodies XAV-19
antibodies, heterophile
conditional marketing authorisation
nirmatrelvir and ritonavir drug combination
nirmatrelvir
nirmatrelvir and ritonavir

---
https://publications.msss.gouv.qc.ca/msss/document-003321/
2022
Canada
COVID-19
public health guidelines
Antiviral drugs
antiviral agents
organization
Organization
Organization
nirmatrelvir and ritonavir drug combination
nirmatrelvir
organizers, embryonic
guideline
Antiviral agents
leadership
organizations
ritonavir

---
https://solidarites-sante.gouv.fr/IMG/pdf/dgs-urgent__2022_22_paxlovid.pdf
2022
false
false
false
France
COVID-19
nirmatrelvir and ritonavir drug combination
nirmatrelvir
nirmatrelvir and ritonavir
scientific and technical information
laboratories
Paxlovid
devices
tablets
dandruff
association
ritonavir
PF-07321332
antiviral agents
Set, Psychology
seborrhea sicca
Antiviral agents
Antiviral drugs
device, nos

---
https://www.has-sante.fr/jcms/p_3311133/fr/paxlovid-pf-07321332/ritonavir
https://has-sante.fr/jcms/p_3311149/fr/decision-n-2022-0023/dc/sem-du-20-janvier-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-paxlovid
2022
false
false
false
France
COVID-19
treatment outcome
drug combinations
ritonavir
antiviral agents
lactams
leucine
proline
nitriles
Viral Protease Inhibitors
adult
guidelines for drug use
administration, oral
continuity of patient care
drug monitoring
data collection
drug interactions
nirmatrelvir and ritonavir drug combination
nirmatrelvir
nirmatrelvir and ritonavir
evaluation of the transparency committee

---
https://ansm.sante.fr/actualites/covid-19-acces-precoce-accorde-au-paxlovid-en-traitement-curatif
2022
false
false
false
France
French
COVID-19
drug combinations
antiviral agents
drug information
ritonavir
lactams
leucine
nitriles
proline
Viral Protease Inhibitors
adult
SARS-CoV-2 variants
nirmatrelvir and ritonavir drug combination
nirmatrelvir
nirmatrelvir and ritonavir

---
https://www.inesss.qc.ca/covid-19/traitements-specifiques-a-la-covid-19/nirmatrelvir-/-ritonavir-paxlovid.html
2022
false
false
false
Canada
COVID-19
nirmatrelvir and ritonavir drug combination
nirmatrelvir
nirmatrelvir and ritonavir
drug evaluation
ritonavir

---
https://publications.msss.gouv.qc.ca/msss/document-003287/
2022
false
false
false
Canada
nirmatrelvir and ritonavir drug combination
nirmatrelvir
nirmatrelvir and ritonavir
public health guidelines
leadership
Antiviral agents
organizers, embryonic
ritonavir
COVID-19
organization
antiviral agents
guideline
Organization
Antiviral drugs
organizations
Organization

---
PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels
https://recalls-rappels.canada.ca/fr/avis-rappel/paxlovid-nirmatrelvir-et-ritonavir-posologie-et-administration-en-presence-insuffisance
2022
false
false
false
Canada
French
English
pharmacovigilance note
canada
drug therapy, combination
ritonavir
antiviral agents
lactams
proline
leucine
nitriles
renal insufficiency
drug interactions
COVID-19
adult
administration, oral
Viral Protease Inhibitors
nirmatrelvir and ritonavir
nirmatrelvir and ritonavir drug combination
nirmatrelvir

---
https://www.has-sante.fr/jcms/p_3334227/fr/paxlovid-pf-07321332-/-ritonavir-covid-19
2022
false
false
false
France
COVID-19
evaluation of the transparency committee
ritonavir
PF-07321332
Paxlovid

---
https://www.has-sante.fr/jcms/p_3186049/fr/veille-des-etudes-cliniques-publiees-pour-certains-medicaments-du-covid-19
2021
false
false
false
France
coronavirus infections
pneumonia, viral
review of literature
hydroxychloroquine
remdesivir
lopinavir-ritonavir drug combination
Clinical Studies as Topic
azithromycin
remdesivir
pneumonia, viral
coronavirus infections
pandemics
alanine
alanine
ribonucleotides
ritonavir
lopinavir
drug combinations
COVID-19

---
https://ansm.sante.fr/actualites/plaquenil-et-kaletra-les-traitements-testes-pour-soigner-les-patients-covid-19-ne-doivent-etre-utilises-qua-lhopital
2020
false
false
false
France
French
hydroxychloroquine
lopinavir-ritonavir drug combination
pharmacovigilance note
guidelines for drug use
hydroxychloroquine
arrhythmias, cardiac
drug monitoring
continuity of patient care
patients guideline
drug interactions
risk factors
coronavirus infections
pneumonia, viral
ritonavir
lopinavir
drug combinations
pneumonia, viral
coronavirus infections
COVID-19
COVID-19

---
https://ansm.sante.fr/actualites/medicaments-utilises-chez-les-patients-atteints-de-la-covid-19-une-surveillance-renforcee-des-effets-indesirables
2020
false
false
false
France
French
pharmacovigilance note
drug monitoring
Off-Label use
lopinavir-ritonavir drug combination
hydroxychloroquine
antiviral agents
cardiovascular diseases
pneumonia, viral
coronavirus infections
pandemics
ritonavir
lopinavir
drug combinations
pneumonia, viral
coronavirus infections
pandemics
COVID-19
COVID-19

---
https://www.has-sante.fr/jcms/p_3215576/fr/kaletra
2020
false
false
false
France
lopinavir and ritonavir
evaluation of the transparency committee
lopinavir-ritonavir drug combination
ritonavir
lopinavir
drug combinations

---
https://ansm.sante.fr/uploads/2020/10/15/20201015-putlopinavir-ritonavir-1.pdf
2020
false
false
false
France
French
Off-Label use
lopinavir-ritonavir drug combination
guidelines for drug use
antiviral agents
drug interactions
lopinavir-ritonavir drug combination
lopinavir-ritonavir drug combination
risk
antiviral agents
antiviral agents
pregnancy
coronavirus infections
pneumonia, viral
ritonavir
lopinavir
drug combinations
pneumonia, viral
coronavirus infections
ritonavir
lopinavir
drug combinations
ritonavir
lopinavir
drug combinations
COVID-19
COVID-19

---
https://sfpt-fr.org/images/documents/STP/Recommandations_STP_ANRS_AC43_Pharmacologie_v2_26_03_20.pdf
2020
false
false
false
France
coronavirus infections
pneumonia, viral
lopinavir-ritonavir drug combination
guideline
hydroxychloroquine
drug monitoring
pandemics
pneumonia, viral
coronavirus infections
pandemics
ritonavir
lopinavir
drug combinations
COVID-19

---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/kaletra-358.html
2020
false
false
false
Canada
treatment outcome
Evidence-Based medicine
lopinavir and ritonavir
drug evaluation
ritonavir
lopinavir
lopinavir-ritonavir drug combination
drug combinations
pneumonia, viral
coronavirus infections
pneumonia, viral
coronavirus infections
pandemics
drug combinations
COVID-19

---
https://www.ansm.sante.fr/actualites/lansm-securise-lacces-aux-traitements-plaquenil-et-kaletra-pour-les-patients-atteints-de-maladie-chronique
2020
false
false
false
France
French
hydroxychloroquine
lopinavir-ritonavir drug combination
arthritis, rheumatoid
hiv infections
lupus erythematosus, discoid
lupus erythematosus, cutaneous
Off-Label use
guidelines for drug use
chronic disease
ritonavir
lopinavir
drug combinations
pneumonia, viral
coronavirus infections
pneumonia, viral
coronavirus infections
COVID-19
COVID-19

---
Maintien du remboursement dans les mêmes conditions
https://www.has-sante.fr/portail/jcms/c_2896415/en/kaletra
2018
true
France
French
lopinavir-ritonavir drug combination
lopinavir-ritonavir drug combination
infant, newborn
infant
child, preschool
lopinavir and ritonavir
adult
adolescent
child
hiv infections
anti-hiv agents
insurance, health, reimbursement
treatment outcome
HIV-1
drug therapy, combination
anti-hiv agents
administration, oral
evaluation of the transparency committee
ritonavir
lopinavir
drug combinations
ritonavir
lopinavir
drug combinations

---
Inscription d'une solution buvable adaptée à l’extension d’indication chez les jeunes enfants et nourrissons âgés de 14 jours à 2 ans.
https://www.has-sante.fr/portail/jcms/c_2831910/fr/kaletra
2018
false
France
French
lopinavir-ritonavir drug combination
lopinavir-ritonavir drug combination
infant, newborn
infant
child, preschool
lopinavir and ritonavir
hiv infections
anti-hiv agents
insurance, health, reimbursement
treatment outcome
HIV-1
drug therapy, combination
anti-hiv agents
administration, oral
evaluation of the transparency committee
ritonavir
lopinavir
drug combinations
ritonavir
lopinavir
drug combinations

---
https://www.ema.europa.eu/medicines/human/EPAR/Ritonavir-Mylan
2017
false
United Kingdom
English
French
syndication feed
drugs, generic
Product containing precisely ritonavir 100 milligram/1 each conventional release oral tablet (clinical drug)
human immunodeficiency virus i infection
hiv protease inhibitors
acquired immunodeficiency syndrome
hiv infections
treatment outcome
administration, oral
adult
child
adolescent
HIV-1
drug therapy, combination
drug interactions
pregnancy
breast feeding
ritonavir
ritonavir
hiv protease inhibitors
drug evaluation, preclinical
ritonavir
package leaflet
summary of product characteristics
drug evaluation

---
http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire&hit=1&r=42484
http://circulaire.legifrance.gouv.fr/pdf/2017/08/cir_42484.pdf
2017
false
false
false
France
French
legislation
insurance, health, reimbursement
hepatitis C, chronic
elbasvir-grazoprevir drug combination
dasabuvir
legislation, drug
antiviral agents
ritonavir
Product containing ombitasvir and paritaprevir and ritonavir in oral dose form (medicinal product form)
ombitasvir
paritaprevir
direct acting antivirals
daclatasvir
administration, oral
Simeprevir
sofosbuvir-velpatasvir drug combination
ledipasvir, sofosbuvir drug combination
Multidisciplinary care conference (procedure)
Interdisciplinary medical team conference (procedure)
dasabuvir
ombitasvir
paritaprevir
daclatasvir
benzofurans
drug combinations
imidazoles
quinoxalines
Sofosbuvir
carbamates
Heterocyclic Compounds, 4 or More Rings
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
sulfonamides
uracil
uracil
anilides
macrocyclic compounds

---
https://www.has-sante.fr/portail/jcms/c_2775799/fr/viekirax-exviera
2017
false
false
false
false
France
French
evaluation of the transparency committee
drug combinations
administration, oral
hepatitis C, chronic
drug therapy, combination
adult
anilides
carbamates
antiviral agents
macrocyclic compounds
ritonavir
sulfonamides
uracil
treatment outcome
insurance, health, reimbursement
Hepatitis C virus genotype 1 (organism)
ombitasvir
dasabuvir
paritaprevir
dasabuvir
ombitasvir, paritaprevir and ritonavir
ombitasvir
dasabuvir
paritaprevir

---
http://www.has-sante.fr/portail/jcms/c_2728866/fr/reevaluation-des-antiviraux-d-action-directe-dans-le-traitement-de-l-hepatite-c
2016
false
false
false
France
French
guidelines for drug use
practice guideline
antiviral agents
hepatitis C, chronic
drug evaluation
Sofosbuvir
administration, oral
Simeprevir
direct acting antivirals
daclatasvir
ledipasvir
ledipasvir, sofosbuvir drug combination
drug therapy, combination
ritonavir
ombitasvir
paritaprevir
dasabuvir
drug resistance, viral
drug interactions
treatment outcome
daclatasvir
ombitasvir
paritaprevir
dasabuvir
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
imidazoles
anilides
carbamates
macrocyclic compounds
sulfonamides
uracil
uracil

---
http://www.has-sante.fr/portail/jcms/c_2633680/fr/antiviraux-d-action-directe
2016
false
false
false
France
French
evaluation of the transparency committee
adult
hepatitis C, chronic
drug therapy, combination
Sofosbuvir
antiviral agents
direct acting antivirals
daclatasvir
Simeprevir
ledipasvir, sofosbuvir drug combination
dasabuvir
drug combinations
ombitasvir
ritonavir
paritaprevir
fibrosis, liver
risk
has patient
hepacivirus
Infections
autoimmune diseases
hepatic fibrosis, nos
fibrosis
hepatitis C virus
human enterovirus 72
hepatitis C, chronic
business
liver cirrhosis
socialism
patients
chronic infectious disease
guideline
antiviral agents
chronic hepatitis, nos
health
case management
hepatitis c virus
hepatitis a virus
dasabuvir
ombitasvir
paritaprevir
daclatasvir
fibrosis
commerce
patients
guideline
benzimidazoles
fluorenes
uridine monophosphate
sulfonamides
uracil
uracil
anilides
carbamates
macrocyclic compounds
imidazoles

---
https://www.ema.europa.eu/medicines/human/EPAR/lopinavirritonavir-mylan
2016
false
United Kingdom
French
English
syndication feed
drugs, generic
Product containing lopinavir and ritonavir (medicinal product)
human immunodeficiency virus i infection
Product containing precisely lopinavir 100 milligram and ritonavir 25 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely lopinavir 200 milligram and ritonavir 50 milligram/1 each conventional release oral tablet (clinical drug)
lopinavir
lopinavir
lopinavir-ritonavir drug combination
lopinavir-ritonavir drug combination
acquired immunodeficiency syndrome
adult
child
drug interactions
hiv protease inhibitors
anti-hiv agents
treatment outcome
drug evaluation
drug combinations
ritonavir
administration, oral
hiv infections
adolescent
anti-hiv agents
hiv protease inhibitors
drug therapy, combination
pregnancy
breast feeding
drug evaluation, preclinical
drug approval
HIV-1
ritonavir
package leaflet
summary of product characteristics
drug evaluation
lopinavir and ritonavir
drug combinations
drug combinations

---
http://www.has-sante.fr/portail/jcms/c_2588368/fr/norvir
2016
false
France
French
human immunodeficiency virus i infection
adolescent
ritonavir
administration, oral
hiv protease inhibitors
ritonavir
insurance, health, reimbursement
drug therapy, combination
adult
child
HIV-1
hiv infections
risk assessment
treatment outcome
evaluation of the transparency committee

---
Information Update - Risk of Serious Liver Injury associated with Hepatitis C Treatments: Holkira Pak and Technivie
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2015/55800a-fra.php
2015
false
false
false
Canada
French
English
Chemical and Drug Induced Liver Injury
pharmacovigilance note
antiviral agents
hepatitis C, chronic
drug combinations
antiviral agents
ombitasvir
paritaprevir
ritonavir
dasabuvir
ombitasvir
dasabuvir
anilides
carbamates
sulfonamides
uracil
uracil
macrocyclic compounds
Contraindications, Drug

---
Viekirax - ombitasvir / paritaprevir / ritonavir
https://www.ema.europa.eu/medicines/human/EPAR/Viekirax
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
anilides
anilides
drug approval
europe
carbamates
carbamates
hepatitis C, chronic
drug therapy, combination
antiviral agents
antiviral agents
macrocyclic compounds
macrocyclic compounds
ritonavir
ritonavir
administration, oral
cytochrome p-450 cyp3a
NS-5 protein, hepatitis C virus
NS4A cofactor peptide, hepatitis C virus
NS3 protein, hepatitis C virus
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
ombitasvir
ombitasvir
paritaprevir
paritaprevir
paritaprevir
paritaprevir
ombitasvir, paritaprevir and ritonavir
viral nonstructural proteins
carrier proteins
viral nonstructural proteins
ombitasvir
ombitasvir

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00250
2015
false
false
false
Canada
French
English
drug information
Product containing ombitasvir and paritaprevir and ritonavir in oral dose form (medicinal product form)
drug combinations
ritonavir
paritaprevir
ombitasvir
ombitasvir, paritaprevir and ritonavir
paritaprevir
ombitasvir
macrocyclic compounds
anilides
carbamates

---
http://www.has-sante.fr/portail/jcms/c_2025737/fr/exviera/viekirax
http://www.has-sante.fr/portail/jcms/c_2025737/fr/viekirax-ombitasvir/paritaprevir/ritonavir-association-fixe-dantiviraux-a-action-directe-exviera-dasabuvir-antiviral-a-action-directe
2015
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
drug combinations
administration, oral
hepatitis C, chronic
drug therapy, combination
adult
anilides
anilides
carbamates
carbamates
antiviral agents
antiviral agents
macrocyclic compounds
macrocyclic compounds
ritonavir
ritonavir
sulfonamides
sulfonamides
uracil
treatment outcome
insurance, health, reimbursement
Hepatitis C virus genotype 1 (organism)
Hepatitis C virus genotype 4 (organism)
ombitasvir
paritaprevir
dasabuvir
paritaprevir
dasabuvir
ombitasvir, paritaprevir and ritonavir
ombitasvir
dasabuvir

---
https://www.ema.europa.eu/medicines/human/EPAR/Norvir
2012
United Kingdom
English
French
syndication feed
Contraindications, Procedure
hiv protease inhibitors
acquired immunodeficiency syndrome
ritonavir
ritonavir
hiv protease inhibitors
hiv protease inhibitors
hiv infections
treatment outcome
drug evaluation
capsules
administration, oral
pharmaceutical solutions
adult
child
adolescent
HIV-1
drug therapy, combination
ritonavir
drug interactions
pregnancy
breast feeding
ritonavir
hiv protease inhibitors
ritonavir
hiv protease inhibitors
ritonavir
ritonavir
hiv protease inhibitors
drug evaluation, preclinical
ritonavir
hiv protease inhibitors
drug compounding
ritonavir
package leaflet
summary of product characteristics
drug evaluation
Contraindications, Drug

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=67851855
2012
France
summary of product characteristics
package leaflet
ritonavir
tablets

---
https://www.ema.europa.eu/medicines/human/EPAR/Kaletra
2012
United Kingdom
French
English
syndication feed
lopinavir
lopinavir
lopinavir-ritonavir drug combination
lopinavir-ritonavir drug combination
acquired immunodeficiency syndrome
adult
child
drug interactions
hiv protease inhibitors
anti-hiv agents
treatment outcome
drug evaluation
drug combinations
ritonavir
tablets
capsules
pharmaceutical solutions
administration, oral
hiv infections
adolescent
anti-hiv agents
hiv protease inhibitors
drug therapy, combination
pregnancy
breast feeding
drug evaluation, preclinical
drug storage
drug labeling
drug approval
HIV-1
ritonavir
package leaflet
summary of product characteristics
drug evaluation
lopinavir and ritonavir

---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-04/norvir_-_ct_-_9674.pdf
http://www.has-sante.fr/portail/jcms/c_1036529/norvir
2011
France
French
ritonavir
administration, oral
hiv protease inhibitors
ritonavir
insurance, health, reimbursement
drug therapy, combination
adult
child
HIV-1
hiv infections
risk assessment
treatment outcome
evaluation of the transparency committee

---
http://www.meddispar.fr/KALETRA-200-B-120/(type)/letter/(value)/K/(cip)/3400949409648
2011
France
French
lopinavir
lopinavir-ritonavir drug combination
drug combinations
ritonavir
administration, oral
drug prescriptions
legislation, drug
anti-hiv agents
drug information
lopinavir and ritonavir

---
http://www.meddispar.fr/medicaments/3440751
2010
France
French
ritonavir
legislation, drug
drug prescriptions
administration, oral
ritonavir
drug information

---
http://www.meddispar.fr/medicaments/3566819
2008
France
French
ritonavir
pharmaceutical solutions
administration, oral
drug combinations
drug prescriptions
legislation, drug
lopinavir
lopinavir-ritonavir drug combination
lopinavir and ritonavir
drug information

---
http://www.meddispar.fr/medicaments/3844201
2008
France
French
lopinavir
lopinavir-ritonavir drug combination
ritonavir
legislation, drug
drug combinations
drug prescriptions
tablets
administration, oral
drug information
lopinavir and ritonavir

---
Nous contacter.
23/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.